护肝胶囊联合硫普罗宁治疗慢性乙型肝炎的临床研究  

Clinical study on Hugan Capsules combined with tiopronin in treatment of chronic hepatitis B

作　　者：贾珍[1] 沈有秀[2] 罗梦琳 JIA Zhen;SHEN You-xiu;LUO Meng-lin(Central Ministry of Transport,Qinghai Provincial People’s Hospital,Xining 810007,China;Department of Gastroenterology,Qinghai Provincial People’s Hospital,Xining 810007,China;Department of Laboratory,Qinghai Provincial People’s Hospital,Xining 810007,China)

机构地区：[1]青海省人民医院中央运输部,青海西宁810007 [2]青海省人民医院消化科,青海西宁810007 [3]青海省人民医院检验科,青海西宁810007

出　　处：《现代药物与临床》2019年第12期3677-3681,共5页Drugs & Clinic

摘　　要：目的探讨护肝胶囊联合硫普罗宁片治疗慢性乙型肝炎的临床疗效。方法选取2017年2月-2018年9月青海省人民医院收治的86例慢性乙型肝炎患者为研究对象,采用随机数字表法将所有患者分为对照组和治疗组,每组各43例。对照组口服硫普罗宁片,0.2g/次,3次/d。治疗组患者在对照组的基础上口服护肝胶囊,4粒/次,3次/d。两组患者均连续治疗3个月。观察两组的临床疗效,比较两组的肝功能指标、肝纤维化指标以及乙型肝炎E抗原(HBeAg)、乙型肝炎表面抗原(HBsAg)、乙型肝炎病毒脱氧核糖核酸(HBV-DNA)转阴情况。结果治疗后,对照组和治疗组的总有效率分别为76.74%、93.02%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者血清总胆红素(TBIL)、丙氨酸氨基转氨酶(ALT)、谷氨酰转肽酶(GGT)、天门冬氨酸氨基转移酶(AST)水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组患者的肝功能指标水平均明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组的层黏连蛋白(LN)、Ⅲ型前胶原(P-CⅢ)、透明质酸酶(HA)水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后治疗组的肝纤维化指标水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组HBeAg、HBsAg、HBV-DNA转阴情况比较差异无统计学意义。结论护肝胶囊联合硫普罗宁片治疗慢性乙型肝炎具有较好的临床疗效,可改善患者肝功能和肝纤维化指标,安全性较好,具有一定的临床推广应用价值。Objective To investigate the clinical efficacy of Hugan Capsules combined with Tiopronin Tablets in treatment of chronic hepatitis B. Methods Patients(86 cases) with chronic hepatitis B in Qinghai Provincial People’s Hospital from February 2017 to September 2018 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Tiopronin Tablets, 0.2 g/time, three times daily. Patients in the treatment group were po administered with Hugan Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and liver function indexes, hepatic fibrosis indexes, negative conversion of HBeAg, HBsAg, and HBV-DNA in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.74% and 93.02%, respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of TBIL, ALT, GGT, and AST in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the liver function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of LN, P-CⅢ, and HA in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the hepatic fibrosis indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, there was no significant difference of HBeAg, HBsAg and HBV-DNA between two groups. Conclusion Hugan Capsules combined with Tiopronin Tablets has clinical curative effect in treatment of chronic hepatitis B, can improve the liver function and liver fibrosis index of patients, with good safety, which has a certain clinical

关 键 词：护肝胶囊 硫普罗宁片 慢性乙型肝炎 肝功能 肝纤维化 HBeAg转阴 HBSAG转阴 HBV-DNA转阴 

分 类 号：R978.7[医药卫生—药品]